News

Biostock-regenerative-medicine-phi

BioStock: PHI expands market potential with regenerative medicine opportunity

BioStock contacted CFO Patrik Eschricht to find out more about PHI’s visions regarding regenerative medicine, cell-based therapies and automatization of biomanufacturing.
Technician checking stem cell culture

Interim Report 1 2022/23

Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
PHIs-CEO-Peter-Egelberg-at-the-RegeneratOR-Test-Bed-at-WFIRM_web

Wake Forest Institute for Regenerative Medicine Welcomes PHI

PHI visits the WFIRM to finalize an agreement concerning the automation of advanced quality control in large-scale biomanufacturing of regenerative therapies.
blue-cells_black-bg_banner

Year-end Report 2021/22

Sales more than doubled in 2021/22, compared to previous financial year.
Artistic image of molecularly imprinted polymers (MIP).

Synthetic antibody patent awarded to PHI by Japan

PHI announces today that the Company has been granted a patent concerning synthetic antibodies in Japan.
Scientists in protective gear working in a cell laboratory.

PHI Enters Biomanufacturing Partnership with Wake Forest Institute for Regenerative Medicine

PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
Close up of female hand signing an agreement

PHI Signs Subscription Commitments with Board Members, CEO and Owners

Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.
Generic Business Image

BioStock: PHIs CEO eyes new business opportunities

BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.
A fluorescence equipped HoloMonitor system operating inside a cell incubator at Novo Nordisk A/S

HoloMonitor Fluorescence Now at Novo Nordisk

PHI recently installed a fluorescence-equipped HoloMonitor® system at Novo Nordisk A/S. The installation is part of a series of test installations to allow experienced HoloMonitor customers to provide feedback regarding functionality and user-friendliness prior to the upcoming product launch.

PHI changes the date for publication of Interim Report 3 2021/22

The reason for the change of date is to allow management and staff to participate in the newly decided rights issue by purchasing shares.
15678920